Literature DB >> 9631413

Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.

B Rho1, S D Glick.   

Abstract

Ibogaine, an alkaloid found in the root bark of the African shrub Tabernanthe iboga, has been claimed to interrupt opioid dependence in humans; in animals, it has been shown to inhibit morphine self-administration and to attenuate signs of morphine withdrawal. However, ibogaine has some neurotoxicity, and because of this, efficacious and safer congeners of ibogaine have been sought, 18-Methoxycoronaridine (18-MC), a novel iboga alkaloid congener, has been shown, in animals, to mimic the effects of ibogaine on morphine self-administration without producing any ibogaine-like neurotoxiticity. In the present study, 18-MC was shown to attenuate five of seven signs of morphine withdrawal in rats. The data suggest that 18-MC will ameliorate symptoms of opioid dependence in humans.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9631413     DOI： 10.1097/00001756-199805110-00004

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  10 in total

1.  18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats.

Authors:  Olga D Taraschenko; Isabelle M Maisonneuve; Stanley D Glick
Journal:  Pharmacol Biochem Behav       Date:  2010-05-10       Impact factor: 3.533

2.  The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

Authors:  P P Muldoon; K J Jackson; E Perez; J L Harenza; S Molas; B Rais; H Anwar; N T Zaveri; R Maldonado; U Maskos; J M McIntosh; M Dierssen; M F Miles; X Chen; M De Biasi; M I Damaj
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4α5 nicotinic acetylcholine receptors.

Authors:  Anne Tammimäki; Penelope Herder; Ping Li; Caroline Esch; James R Laughlin; Gustav Akk; Jerry A Stitzel
Journal:  Neuropharmacology       Date:  2012-07-20       Impact factor: 5.250

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 5.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

6.  Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.

Authors:  Stanley D Glick; Elizabeth M Sell; Sarah E McCallum; Isabelle M Maisonneuve
Journal:  Eur J Pharmacol       Date:  2011-08-19       Impact factor: 4.432

7.  Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine.

Authors:  Erika Perez; Natalia Quijano-Cardé; Mariella De Biasi
Journal:  Neuropsychopharmacology       Date:  2015-03-19       Impact factor: 7.853

8.  18-methoxycoronaridine: a potential new treatment for obesity in rats?

Authors:  Olga D Taraschenko; Heather Y Rubbinaccio; Isabelle M Maisonneuve; Stanley D Glick
Journal:  Psychopharmacology (Berl)       Date:  2008-08-28       Impact factor: 4.530

9.  Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Authors:  Tamara Antonio; Steven R Childers; Richard B Rothman; Christina M Dersch; Christine King; Martin Kuehne; William G Bornmann; Amy J Eshleman; Aaron Janowsky; Eric R Simon; Maarten E A Reith; Kenneth Alper
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Endogenous cholinergic neurotransmission contributes to behavioral sensitization to morphine.

Authors:  Dusica Bajic; Mariano Soiza-Reilly; Allegra L Spalding; Charles B Berde; Kathryn G Commons
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.